Result of Annual General Meeting
Cambridge, UK, 30 June 2021 - 4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of gene therapies and vaccines, announces that all of the resolutions proposed at its Annual General Meeting held earlier today were duly passed. A poll was held on each of the resolutions.
The resolutions passed include a resolution to approve the conversion of the Company from a UK Societas into a public limited liability company registered in England and Wales (“PLC”). The Company will proceed with the requisite filings and update the market in due course.
The Company's issued share capital was 12,317,473 ordinary shares of €1 each and the full results of the poll
The Company will review the proxy submission process for future General Meetings, with a view to streamlining the process where possible.
The Company also wishes to again draw attention to the investor meeting being held tomorrow, 1 July 2021, through the Investor Meet Company platform at 10.00am. Investors can sign up to Investor Meet Company for free and register interest here: https://www.investormeetcompany.com/4basebio-uk-societas/register-investor
This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
For further enquiries, please contact:
4basebio UK Societas: Heikki Lanckriet, CEO +44 (0)12 2396 7943
Cairn Financial Advisers LLP (Nominated Adviser): Jo Turner / Sandy Jamieson +44 (0)20 7213 0880
finnCap Ltd (Broker): Geoff Nash/Richard Chambers/Charlotte Sutcliffe +44 (0)20 7220 0500
Walbrook PR: +44 (0)20 7933 8780
Anna Dunphy / Paul McManus: Mob: +44 (0)7876 441 001 / +44 (0)7980 541 893
Notes to Editors
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is the intention of the Company to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The immediate objectives of 4bb are to validate and scale its DNA synthesis and advance its collaborations to facilitate the functional validation of its DNA based products and gene delivery solutions.
The Company divested from 4basebio AG (“4bb AG”), a German company listed on the Prime Standard segment of the Frankfurt Stock Exchange, following the disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology business to AIM-quoted Abcam plc in January 2020 for €120million. Following the disposal, 4bb AG retained its genomics business which owned and licensed certain intellectual property including its proprietary, patent-protected technology, TruePrime™. This is the foundation for building the Company’s synthetic DNA manufacturing business which 4bb AG transferred to the Company along with funding to continue the Company’s development and investment.